Benefits of Antidepressants in Fibromyalgia

Home>
Specialties>
General Medicine>
Summary and Comment

Benefits of Antidepressants in Fibromyalgia

Tricyclic antidepressants were effective in reducing pain, fatigue, and sleep disturbances.

Antidepressants commonly are prescribed for patients with fibromyalgia (FM), even for those who don’t meet criteria for clinical depression, but the magnitude of benefit associated with antidepressant therapy is unclear. In a meta-analysis, German investigators examined data from 18 randomized controlled trials of antidepressants for FM treatment that met criteria for high methodological quality (combined enrollment, 1427 subjects; mean study duration, 8 weeks).

Tricyclic antidepressants (TCAs) in small doses (12.5–50 mg daily) had large effect sizes for reducing pain, fatigue, and sleep disturbances; the average benefit in treated subjects was greater than that experienced by about 90% of controls. Compared with TCAs, the effect sizes for selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for reducing pain and other endpoints were smaller. Median rates of adverse effects were roughly similar in treated and control subjects.

Comment: Whereas antidepressants of all categories provide moderate pain relief to FM patients, TCAs provide the most pain benefit and reduce fatigue and sleep disturbances as well. Currently, duloxetine (Cymbalta) — an SNRI — is the only antidepressant approved for use in patients with FM, but, in this analysis, SNRIs had a smaller effect on pain than did the other classes.

— Thomas L. Schwenk, MD

Published in Journal Watch General Medicine January 22, 2009

Citation(s):

Häuser W et al. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA 2009 Jan 14; 301:198.

Medline abstract (Free)

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Remark subject:*

Your remark:*

Fields marked with an * are required.

Name as you'd like it to appear:
First & middle initial:*

Last:*

Email address (will not
be published):*

Professional specialty:*

Place of work (optional):

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

No competing interests

Or, the following competing interests (for example, financial stakes or professional relationships):

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.